Phases of volume loss in patients with known frontotemporal lobar degeneration spectrum pathology

Neurobiol Aging. 2022 May:113:95-107. doi: 10.1016/j.neurobiolaging.2022.02.007. Epub 2022 Feb 24.

Abstract

Frontotemporal lobar degeneration (FTLD) includes clinically similar FTLD-tau or FTLD-TDP proteinopathies which lack in vivo markers for accurate antemortem diagnosis. To identify early distinguishing sites of cortical atrophy between groups, we retrospectively analyzed in vivo volumetric MRI from 42 FTLD-Tau and 21 FTLD-TDP patients and validated these findings with postmortem measures of pathological burden. Our frequency-based staging model revealed distinct loci of maximal early cortical atrophy in each group, including dorsolateral and medial frontal regions in FTLD-Tau and ventral frontal and anterior temporal regions in FTLD-TDP. Sørenson-Dice calculations between proteinopathy groups showed little overlap of phases. Conversely, within-group subtypes showed good overlap between 3R- and 4R-tauopathies, and between TDP-43 Types A and C for early regions with subtle divergence between subtypes in subsequent phases of atrophy. Postmortem validation found an association of imaging phases with pathologic burden within FTLD-tau (F(4, 238) = 17.44, p < 0.001) and FTLD-TDP (F(4,245) = 42.32, p < 0.001). These results suggest that relatively early, distinct markers of atrophy may distinguish FTLD proteinopathies during life.

Keywords: Frontotemporal lobar degeneration; Magnetic resonance imaging; Percent area occupied; Sporadic; TDP-43; Tau.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Atrophy
  • Biomarkers
  • Frontotemporal Dementia* / pathology
  • Frontotemporal Lobar Degeneration* / diagnostic imaging
  • Frontotemporal Lobar Degeneration* / pathology
  • Humans
  • Retrospective Studies
  • tau Proteins

Substances

  • Biomarkers
  • tau Proteins